Growth Hormone Secretagogue
Tesamorelin
FDA-approved GHRH analog (Egrifta) for visceral fat reduction with Phase III clinical trial data.
Evidence: 2 articles
Goals: 1
Mechanism of Action
Bioregulator compound with targeted biochemical activity.
Evidence Level
Preclinical Model
2 studies published